A Feasibility Study of Roquinimex (Linomide) and Alpha Interferon in Patients With Advanced Malignant Melanoma or Renal Carcinoma

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.1998.732
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Randomised Dose Escalation Study of Subcutaneous Interleukin 2 With and Without Levamisole in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma

British Journal of Cancer
Cancer ResearchOncology
1996English

Alpha-Interferon Therapy in a Patient With Renal Cell Carcinoma and Renal Hypofunction

Japanese Journal of Urology
Urology
1995English

Interferon-Alfa in the Treatment of Patients With Inoperable Locally Advanced or Metastatic Renal Cell Carcinoma: A Systematic Review

Canadian Urological Association Journal
Urology
2013English

A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2014English

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab

JAMA Oncology
Cancer ResearchOncology
2019English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

Prognostic Factors in 161 Patients With Mucosal Melanoma: A Study of German Central Malignant Melanoma Registry

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2020English

E3611- A Randomized Phase II Study of Ipilimumab at 3 or 10 Mg/Kg Alone or in Combination With High Dose Interferon-Α2b in Advanced Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2018English

A Phase II Randomised Trial of 5-Fluorouracil With or Without Interferon Alpha-2a in Advanced Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
1996English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy